Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Patients with grade 3 neuroendocrine neoplasm (NEN G3) have a limited prognosis. Even in a non-metastatic stage, the risk of recurrence after surgery is high. Multimodal perioperative treatment, including chemotherapy and/or radiotherapy in an adjuvant or neoadjuvant setting, has improved the prognosis in numerous tumor entities; however, it has not been systematically evaluated in NEN G3 so far. Nevertheless, perioperative chemotherapy is generally recommended in most current treatment guidelines for NEN G3.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Apostolidis L, Starke H, Bhatti I, Jäger D, Winkler E,
Keywords: NEN G3, neuroendocrine carcinoma, adjuvant, neoadjuvant, surgery,
#3079 Novel Symptoms and Therapy of Multiple Endocrine Neoplasia Type 1
Introduction: MEN1 is a rare autosomal inherited disease with hallmark of hyperparathyroidism, duodenopancreatic NENs and pituitary tumor.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: bai J
Keywords: MEN1, LGCS, NENs, gastrinoma, Parathyroid carcinoma,
Introduction: In spite of new treatments like PRRT or everolimus there is a clinical need for systemic therapies that complement SSAs (somatostatin analogs) and antidiarrheal agents in the treatment of carcinoid syndrome, a late stage problem in s-i-NET. Telotristat is a promising addition to our therapeutic arsenal.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Linder Ekberg K,
Keywords: telotristat, carcinoid syndrome, metastasized GI-NET,
Introduction: Rb and p53 status may help distinguishing well from poorly differentiated neuroendocrine neoplasms (NEN) and may predict response to chemotherapy. Studies correlating Rb/p53 genetic and immunohistochemistry were performed on high-quality frozen samples with high throughput techniques efficient for copy number determination. This situation differs from routine practice in which small deletions may be hard to detect on formalin-fixed paraffin-embedded (FFPE) samples with a gene panel approach.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Cros J
Authors: Chen R, Lacroix L, De Rycke O, Lacombe C, Cazes A,
Keywords: rb, p53, aggressive neuroendocrine tumors, biomarker,
#3070 Activity and Safety of Avelumab in Merkel Cell Carcinoma: Our Experience
Introduction: Merkel cell carcinoma (MCC) is an aggressive neuroendocrine carcinoma of the skin. The use of checkpoint inhibitors has shown good results in the treatment of advanced MCC. Avelumab is a PD-L1 inhibitor able to prevent the inactivation of the T lymphocytes. We report a serie of consecutive MCC cases treated with Avelumab in two centres
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Giuffrida D
Authors: Puliafito I, Sciacca D, Bonasera A, Blanco G, Iacono F,